Pfizer (PFE) Tax Provisions (2009 - 2026)

Pfizer (PFE) has reported Tax Provisions for 18 consecutive years, with -$407.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Tax Provisions fell 388.65% year-over-year to -$407.0 million in Q2 2026; TTM through Jun 2026 was -$164.0 million, a 177.73% decrease from a year earlier, with the FY2025 full-year figure at -$266.0 million, down 850.0% from the prior year.
• Tax Provisions was -$407.0 million for Q2 2026 at Pfizer, down from $461.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $1.6 billion in Q3 2022 and troughed at -$795.0 million in Q4 2023.
• A 5-year average of $209.4 million and a median of $69.5 million in 2025 frame the typical range for Tax Provisions.
• The widest YoY moves for Tax Provisions: up 343.92% in 2026, down 388.65% in 2026.
• Over 5 years, Tax Provisions stood at $1.6 billion in 2022, then tumbled by 150.64% to -$795.0 million in 2023, then soared by 149.43% to $393.0 million in 2024, then slumped by 100.51% to -$2.0 million in 2025, then tumbled by 20250.0% to -$407.0 million in 2026.
• The last three Tax Provisions figures came in at -$407.0 million (Q2 2026), $461.0 million (Q1 2026), and -$2.0 million (Q4 2025), per Business Quant data.